MedMira Reports Third Quarter Results FY2023
HALIFAX, NS / ACCESSWIRE / June 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2023. Corporate Update Summary During the third ...
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. In addition, the company offers VYRATM TriDemic antigen rapid test that distinguishes the three respiratory viruses, such as SARS-CoV-2, influenza, and respiratory syncytial virus that exhibit similar symptoms. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
0.0542 | |
0.0542 | |
- | |
0.0542 | |
0.0542 | |
0.0121-0.2 | |
41 555 K | |
702 M | |
383 K | |
-0.0008 | |
10.761 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
HALIFAX, NS / ACCESSWIRE / June 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2023. Corporate Update Summary During the third ...
MedMira (CVE:MIR) Second Quarter 2023 Results Key Financial Results Revenue: CA$170.5k (down 43% from 2Q 2022). Net loss: CA$490.5k (loss widened by 4.7% from 2Q 2022). CA$0.001 loss per share (in l...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: